The People Who Brought You Cheaper Hepatitis C Drugs Are Going After Cancer Next

Express Scripts, which this year forced price concessions from makers of $1,000-a-day hepatitis C medicines, has set its sights on $37 billion in U.S. spending on cancer medications. Its goal is to start influencing the drugs’ costs as soon as next year.

Read More